An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Per Olsson GisleskogBelén ValenzuelaTatiana ScherzMichel BurcklenJuan Jose Perez RuixoItalo PoggesiPublished in: Clinical pharmacokinetics (2021)
ClinicalTrials.gov Identifier: NCT01006265, registration date 1 November, 2009.